Total knee arthroplasty in Brown-Séquard syndrome.

BMJ Case RepSep 21, 2026 (epub)
Case ReportOrthopedic Surgery

Arin Mahmoud, Rajendran Sucharita, Dawn Harpham et al.

✦ AI-curated · Sources linked

Case in brief

A patient with Brown-Séquard syndrome presented with severe neuropathic pain due to osteoarthritis. After conservative treatments failed, total knee arthroplasty was performed. Pain levels, measured using the EuroQol Visual Analogue Scale, significantly improved from 90 preoperatively to 0 at one year post-surgery, indicating successful pain management.

Diagnostic / clinical pearl

This case highlights that total knee arthroplasty can be effective for managing neuropathic pain in patients with Brown-Séquard syndrome, challenging traditional views on pain types in osteoarthritis.

Source

PubMed · PMID 42767785

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.